Compare CTKB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | TRDA |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 275.3M |
| IPO Year | 2021 | 2021 |
| Metric | CTKB | TRDA |
|---|---|---|
| Price | $5.72 | $6.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.63 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 281.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,015,000.00 | $25,421,000.00 |
| Revenue This Year | $5.42 | $39.97 |
| Revenue Next Year | $7.03 | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $3.31 | $5.56 |
| 52 Week High | $6.18 | $16.45 |
| Indicator | CTKB | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.64 | 36.99 |
| Support Level | $4.17 | $5.71 |
| Resistance Level | $6.04 | $7.89 |
| Average True Range (ATR) | 0.25 | 0.38 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 88.64 | 16.80 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.